Many of us at Merck Animal Health are pet owners. The science of healthier animals drives everything we do – helping to ensure the safety and well-being of your pet is our top priority.
We know how important it is to make sure you have accurate information about our products in order to feel comfortable and confident about the medications you are giving to your pet. We encourage you to speak with your veterinarian to discuss what’s best for you. This site is dedicated to giving you the facts about BRAVECTO®, our flea and tick medication.
Get the Facts
Setting the Record Straight
We know that protecting your pet’s health can be emotional. After all, many of us at Merck Animal Health have our own fur babies who are true members of our families. However, don’t let hearsay, conjecture and opinion be a substitute for truth — get the facts and discuss your questions with your trusted veterinary professional.
It’s easy to find all sorts of information about veterinary medicines across the internet — especially on social media. Unfortunately, much of the information shared on social media is simply inaccurate. You deserve the facts — the complete facts — on BRAVECTO®. If you would like more information please consult a trusted veterinary professional, or visit us.bravecto.com.
BRAVECTO® DOESN’T WORK
More than 170 clinical trials prove that BRAVECTO® is safe and effective against the most common fleas and ticks. It works quickly too, killing these parasites within hours.
SIDE EFFECTS FROM TAKING BRAVECTO® CAN SHOW UP LONG AFTER THE DOSE
Following the approval of an animal health drug, companies are required to continue monitoring the drug to ensure the safety and efficacy through an objective, science-based lens. Throughout the monitoring process, we report adverse effects to the appropriate governing body as required by law. This monitoring and scientific assessment continue to support BRAVECTO® safety. Since BRAVECTO® was approved in 2014, more than 175 million doses have been distributed around the world, which reflects the trust and confidence of both pet owners and vets. There is no question in our confidence in the safety and efficacy profile of BRAVECTO®.
NEGATIVE INCIDENTS USING BRAVECTO® ARE INCREASING
This is simply not the case. Based on the most recent Periodic Safety Update Report (PSUR), which was assessed by the European Medicines Agency (the EU equivalent to the FDA), the incidence of all adverse events remains categorized as “rare.” That means adverse events are occurring in between 1/10,000 (0.01%) and 1/1,000 (0.1%). The most common reported events are mild and transient gastrointestinal upset, which are noted on the product label. An adverse event report also does not mean causation.
In today’s digital age, social media can present a misleading picture. We recommend you consult your veterinarian to gain the fullest, most accurate picture of your pet’s health and ask them about BRAVECTO®.
HOLISTIC MEDICINE PROVIDES A MORE EFFECTIVE ALTERNATIVE TO FLEA AND TICK MEDICATION
Fleas and ticks are not just a nuisance, they also pose significant health risks, as they can transmit diseases (including Lyme disease, Rocky Mountain Spotted Fever, Bartonellosis and others).
Alternative methods for treating fleas and ticks are available. However, unlike holistic treatments, BRAVECTO® has undergone the stringent testing and trials needed for regulatory approvals, and is monitored by regulatory agencies across the globe.
For any questions or concerns please contact the Merck Animal Health Companion Animal Technical Services and Pharmacovigilance Team:
800-224-5318 ~ 9 AM to 7 PM EST
1 All data on file. Merck Animal Health.
* BRAVECTO® kills fleas and prevents flea infestations. BRAVECTO® Chew and BRAVECTO® Topical for Dogs kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks and also kills lone star ticks for 8 weeks. BRAVECTO® Topical for Cats kills ticks (black-legged tick) for 12 weeks and American dog ticks for 8 weeks.
IMPORTANT SAFETY INFORMATION:
BRAVECTO® has not been shown to be effective for 12-weeks’ duration in puppies or kittens less than 6 months of age. Fluralaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. BRAVECTO® Chew: The most commonly reported adverse reactions include vomiting, decreased appetite, diarrhea, lethargy, polydipsia, and flatulence. BRAVECTO® is not effective against lone star ticks beyond 8 weeks of dosing. Seizures have been reported in dogs receiving isoxoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. BRAVECTO® Topical Solution for Dogs: The most commonly reported adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash. BRAVECTO® is not effective against lone star ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. Seizures have been reported in dogs receiving fluralaner, even in dogs without a history of seizures. Use caution in dogs with a history of seizures or neurologic disorders. BRAVECTO® Topical Solution for Cats: The most commonly reported adverse reactions include vomiting, itching, diarrhea, hair loss, decreased appetite, lethargy, and scabs/ulcerated lesions. BRAVECTO® is not effective against American dog ticks beyond 8 weeks of dosing. For topical use only. Avoid oral ingestion. The safety of BRAVECTO® has not been established in breeding, pregnant and lactating cats. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders.